Compositions and methods for self-adjuvanting vaccines against microbes and tumors

Patent metadata

Field	Value
Publication number	US-10265394-B2
Application number	US-201715461336-A
Country	US
Kind code	B2
Filing date	Mar 16, 2017
Priority date	Mar 23, 2010
Publication date	Apr 23, 2019
Grant date	Apr 23, 2019

Abstract

The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immunostimulatory intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracellular signaling peptide must be present in a complex of three or more units in order to stimulate an immune response. Inserting this fusion construct into viruses like HIV-1 or introducing it into dendritic cells or tumor cells is predicted to lead to a positive therapeutic effect in humans, non-human mammals, birds, and fish.

First claim

What is claimed is:

1. A method for stimulating an immune response in a subject by administering to the subject an isolated nucleic acid, isolated virus, isolated microbe, or isolated host cell, comprising:
(i) a first expression cassette for expressing a protein, wherein said protein comprises the multimerizing domain from the N-terminus of Latent Membrane Protein 1 (LMP1) operatively joined to a cytoplasmic signaling domain of a receptor such that the protein assembles into a complex of three or more protein moieties, and wherein the cytoplasmic signaling domain is from either:
a) a member of the Tumor Necrosis Factor Receptor Superfamily (TNFRSF) or
b) LMP1; and

(ii) a second expression cassette for expressing a protein antigen, with the proviso that the protein antigen is not an Epstein-Barr virus (EBV) protein, and
wherein the nucleic acid encoding any of the LMP1 sequences in the first expression cassette lacks introns.

2. The method of claim 1 , wherein the first and second expression cassettes are contained within the same polynucleotide molecule.

3. The method of claim 1 , wherein the first and second expression cassettes are present on an in vitro synthesized RNA molecule.

4. The method of claim 1 , wherein the first and second expression cassettes are contained within an isolated virus or within an isolated microbe, wherein the isolated virus is selected from the group consisting of Human immunodeficiency virus-1 (HIV-1), Simian immunodeficiency virus (SIV), influenza virus, parainfluenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, adenovirus, adeno-associated virus, Simian virus 40 (SV 40), Modified Vaccinia Ankara (MVA), an arenavirus, a bunyavirus, a fiavivirus, Venezuelan equine encephalitis virus, Eastern equine encephalitis virus, Western equine encephalitis, herpesvirus, measles virus, rhabdoviruses, and combinations thereof, and wherein the isolated microbe is selected from Listeria, Salmonella , and combinations thereof.

5. The method of claim 4 , wherein the isolated virus or isolated microbe comprises the following:
1) a delivery system other than Epstein-Barr virus (EBV);
2) the protein encoded by the first expression cassette; and
3) the protein antigen encoded by the second expression cassette,
wherein the protein antigen is selected from the group consisting of a tumor antigen, a viral antigen, and a microbial antigen.

6. The method of claim 1 , wherein the first and second expression cassettes are contained within two different polynucleotide molecules.

7. The method of claim 3 , wherein the RNA molecule is modified.

8. The method of claim 5 , wherein the protein antigen is endogenous to the isolated virus or the isolated microbe.

9. The method of claim 5 , wherein the protein antigen is not normally expressed by the isolated virus or the isolated microbe.

10. The method of claim 4 , wherein the herpesvirus is cytomegalovirus.

11. The method of claim 4 , wherein the flavivirus is dengue virus, West Nile virus, or Japanese Encephalitis virus.

12. The method of claim 4 , wherein the rhabdovirus is Vesicular Stomatitis virus.

Assignees

• Univ California

Inventors

• Kornbluth Richard Syd
• Stone Geoffrey William

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• C12N2710/16222

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2710/16632

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title